Compare Credo Technology Group Holding Ltd (CRDO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Viatris Inc — how do they compare? Credo Technology Group Holding Ltd trades at $216.27 (market cap $39.82B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Viatris Inc for 57 Days on average.
| CRDO | VTRS | |
|---|---|---|
Market Cap | $39.82B | $20.03B |
Volume | 9,451,558 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $302.52 | $18.27 |
52-Week Low | $87.81 | $9.74 |
Typical Hold Time | 22 Days | 57 Days |
Enterprise Value | $39.08B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $212.42, down 3.45% today but maintains strong technical support near $204 with bullish moving averages. The company demonstrates exceptional fundamentals with 114.7% YoY revenue growth (Seeking Alpha, 2026-09-25) and 33.83% net margins, though valuation remains elevated at P/E of 74.6. Recent earnings beats and AI infrastructure demand drive positive sentiment.
Outlook remains positive given triple-digit revenue growth and $267.33 analyst price target (87.5% buy ratings), but premium valuation and customer concentration pose risks. The stock offers exposure to AI connectivity chip demand with potential for 26% upside to consensus target, though execution risks require monitoring.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
